These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37081733)
1. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Amanam I; Yao J; Puing A; Tsai NC; Samuels D; Ngo D; Ho S; Ali H; Aribi A; Arslan S; Artz A; Htut M; Koller P; Salhotra A; Sandhu K; Nikolaenko L; Pawlowska A; Shouse G; Stein A; Marcucci G; Forman S; Nakamura R; Dadwal S; Al Malki MM Cancer Med; 2023 May; 12(10):11248-11253. PubMed ID: 37081733 [TBL] [Abstract][Full Text] [Related]
2. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987 [TBL] [Abstract][Full Text] [Related]
3. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC Trials; 2021 May; 22(1):363. PubMed ID: 34034784 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series. Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345 [TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study. Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital. Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients. Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573 [TBL] [Abstract][Full Text] [Related]